{"url_path":"/sec/aim/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-024760-index.html","accession_number":"0001493152-26-024760","cik":"0000946644","ticker":"AIM","issuer_name":"AIM ImmunoTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-024760-index.html","primary_entity_key":"0000946644","primary_entity_name":"AIM ImmunoTech Inc."},"word_count":117,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n4.1\n \n[Form of Common Warrant.](ex4-1.htm)\n\n4.2\n \n[Form of Placement Agent Warrant.](ex4-2.htm)\n\n5.1\n \n[Opinion of Thompson Hine LLP, dated May 21, 2026](ex5-1.htm)\n\n10.1\n \n[Securities Purchase Agreement, dated May 20, 2026.](ex10-1.htm)\n\n10.2\n \n[Placement Agency Agreement, dated May 20, 2026.](ex10-2.htm)\n\n23.1\n \n[Consent of Thompson Hine LLP (included in Exhibit 5.1 above)](ex5-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the\nInline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate: May 21, 2026\n**AIM ImmunoTech Inc.**\n\n \n \n\n \n*/s/\nThomas K. Equels*\n\n \nThomas K. Equels\n\n \nChief Executive Officer"}